Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Q&A: First patient dosed in IgGenix ACCELERATE Peanut phase 1 clinical trial
IgGenix announced the first patient dosed with IGNX001, a monoclonal antibody therapeutic for peanut allergy, in the ACCELERATE Peanut phase 1 clinical trial. The trial aims to assess safety, tolerability, and proof of mechanism in patients aged 15 years and older. IGNX001 attaches to peanut proteins to neutralize them, differing from other immunotherapies like Palforzia and Xolair. The trial is ongoing in Australia, with recruitment targeting older adolescents and adults, and initial results expected mid-2025.
More Than 110 Organizations Call on Congress to Reauthorize PAHPA Before End of Year
110+ organizations urge Congress to reauthorize PAHPA by Dec 31, recognizing the opportunity to strengthen national health security during the 2025 leadership transition.
Sarclisa recommended for EU approval by the CHMP to treat transplant ...
CHMP recommends EU approval of Sarclisa with VRd for transplant-ineligible NDMM, based on IMROZ phase 3 study showing improved PFS. If approved, Sarclisa would be the first anti-CD38 therapy in the EU for this combination.
Sarclisa recommended for EU approval by the
CHMP recommends EU approval of Sarclisa with VRd for transplant-ineligible NDMM, based on IMROZ phase 3 study showing improved PFS. If approved, Sarclisa would be the first anti-CD38 therapy in the EU for this use.
Sanofi, Formation and OpenAI design AI tool to slash clinical trial timelines
Sanofi, Formation Bio, and OpenAI collaborate to create Muse, an AI tool accelerating clinical trial recruitment. Muse compiles disease research, identifies ideal patient profiles, and auto-generates customized recruitment materials, aiming to reduce recruitment time to minutes.
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Cabaletta Bio reports Q3 2024 financial results, with $183M in cash, cash equivalents, and short-term investments, supporting operations into H1 2026. Clinical data from RESET-Myositis™, RESET-SLE™, and initial RESET-SSc™ trials to be presented at ACR Convergence 2024. 16 patients enrolled, 10 dosed in the RESET™ program, with 40 U.S. clinical sites actively recruiting. Plans to meet with FDA in 2025 for potential registrational program designs for CABA-201. Clinical development expands into Europe with EMA CTA authorization for CABA-201 in lupus; Gerwin Winter appointed as Senior VP and Head of International.
Cabaletta Bio Expands Clinical Trials to 40 Sites, Reports $183M Cash Position
Cabaletta Bio reported Q3 2024 financial results and business updates, with 40 U.S. clinical sites actively recruiting patients across its RESET clinical trials, 16 enrolled and 10 dosed as of November 12. Clinical data from RESET-Myositis, RESET-SLE, and initial data from RESET-SSc trials will be presented at ACR Convergence 2024. The company received EMA CTA authorization for CABA-201 in lupus, expanding into Europe. Cash position stands at $183.0 million as of September 30, 2024, expected to fund operations into first half of 2026.
AI Collaboration Between Sanofi and Healx Will Target Novel Rare Diseases Indications
Sanofi partners with Healx to use AI for identifying rare disease indications for a discontinued drug asset. Healx will employ its AI platform, Healnet, to analyze Sanofi's drug data and provide therapeutic rationale. The collaboration aims to accelerate the discovery of potential therapies for patients with limited treatment options.
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space
DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report highlights 75+ companies developing 80+ therapies, including promising candidates like GA Depot, Remibrutinib, and IMU 838. Key events include Immunic's positive Phase 3 ENSURE trial interim analysis, Roche's FDA approval for Ocrevus injectable, and Sanofi's mixed results for tolebrutinib in Phase III trials. The report covers global pipeline stages, product types, molecule types, mechanisms of action, and routes of administration.
Other news to note for Nov. 13, 2024
Biopharma updates: deals, partnerships, grants, preclinical data, and other news involving 23andme, Centessa, Egenesis, Enveric, Formation, Kancera, Medicinova, Mycomedica, Organox, Sanofi.
© Copyright 2024. All Rights Reserved by MedPath